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Introduction
Our department recently received a letter of referral from an otolaryngologist concerning a 31-year-old Caucasian
male with inoperable (T4N2c) squamous cell cancer of the base of his tongue. According to this letter, a brother
of the patient had died from early-onset cancer of the soft palate a few years ago. The patient and his two
healthy siblings were referred with the question whether or not a hereditary cancer-predisposing disorder was
present in this family. The letter also mentioned the fact that the patient would receive an experimental combination
of radiation treatment and chemotherapy. 
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Without knowing any further clinical details, the
possibility of Fanconi anaemia (FA) [1] crossed our
minds. Oral cancer is a very rare diagnosis in young
individuals from the Dutch general population, with
incidence rates per 100,000 person-years being smaller
than 0.5 for cancer of the palate or tongue in the 30-
34-year age group [2]. Fanconi anaemia, an autosomal
recessive disorder, is associated with early-onset head
and neck cancer and a range of other neoplasms [3-
5]. The fact that no congenital anomalies had been
mentioned in the referral letter did not exclude the
possibility of FA, because either the otolaryngologist
might not have realized their importance with respect to
a genetic diagnosis, or they simply had not been present
as would be expected in up to one-third of FA patients
[6]. We were concerned about the scheduled treatment
because of the strongly increased risk of complications
after therapy with mutagenic agents (chemical or
radiation) in FA patients [3, 7-10]. Immediately but
unsuccessfully, we tried to contact the referring physician
by telephone. An urgent letter was therefore sent to this
physician, mentioning the fact that FA was at least
a theoretical possibility in this patient (who we had not
seen yet) and might severely complicate his treatment.
An offer to quickly test the patient’s lymphocytes for signs
of FA (increased chromosomal breakage and structural
rearrangements after culture with the DNA cross-linking
agent mitomycin C) was included. We also contacted
the family physician who informed us that the patient
had declined further treatment and had already died
around the time we received the letter of referral. Upon
explaining the reason for our inquiry, we were surprised
to learn that the deceased brother of the patient had
indeed been diagnosed with FA as a child! The old
medical files of both brothers were retrieved. 
The brother of the referred patient had been
diagnosed with Fanconi anaemia in his late teens on
the basis of pancytopenia, increased HbF, short
stature (<P3, skeletal age several years behind
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calendar age), horse-shoe kidney, axillary and
inguinal hyperpigmentation, a few café-au-lait spots
on the skin and increased chromosomal breakage
typical for FA. He was diagnosed with squamous cell
cancer of the soft palate at the age of 31 and died
at the age of 34 (no details on treatment are
available). His younger brother (the referred patient)
had been diagnosed as a teen with short stature
(<P3, skeletal age several years behind calendar
age), persistent mild leukopenia and thrombopenia
and a severe congenital sub-pelvic stenosis of one of
his kidneys. Although the patient had not been tested
for chromosomal breakage, it is fair to assume that
he had FA as well. For reasons unknown to us, the
referring otolaryngologist had not been aware of the
diagnosis of FA in this family or had not realised its
association with head and neck cancer. 
The parents and their two healthy adult children 
(i.e. sibs of the deceased patients) were seen at our
familial cancer clinic. At their own request, the children
were tested for chromosomal breakage and
rearrangements, with normal results. The parents as
well as their children expressed sincere amazement
after learning about the diagnosis of FA in their family
and its association with head and neck cancer and
other neoplasms. The parents could not recollect
having ever heard about this disorder before, although
we assume that the paediatricians have discussed it
with them many years ago. No follow-up aimed at
early detection of cancer had apparently been
performed in their adult sons with FA. Current FA
guidelines do advise such surveillance [5, 11] and
include gynaecological examination and Pap smears,
annual rectal examination, and frequent dental and
oropharyngeal examinations. Annual oesophageal
endoscopy has also been recommended. We cannot
help feeling that if medical (oncological) surveillance
had been more aggressively pursued after childhood
in these two brothers with Fanconi anaemia, their early
deaths might have been prevented. This case also
makes one wonder which proportion of FA patients that
reach adulthood and are lost to paediatric follow-up,
are actually under recommended oncological
surveillance. We would like to conclude this paper on
a more positive note. This clinical history illustrates the
increasing trend we observe among clinicians from
disciplines that did not traditionally refer many patients
for (onco)genetic analysis, to recognise early-onset
cancer as an important warning sign of inherited
cancer predisposition and to consult a family cancer
clinic in those cases. An overview of referral guidelines
for cancer genetics consultations has recently been
published [12]. To those we would like to add that in
the case of early-onset head and neck cancer, the
possibility of Fanconi anaemia, and therefore referral,
should always be very seriously considered. 
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